article thumbnail

Philips launches Duo Venous Stent System for Treatment of Symptomatic Venous Outflow Obstruction

DAIC

and an investigator in the VIVID study , which contributed to the device’s FDA approval – successfully used the Duo Venous Stent System for the first time outside of a clinical trial. It is the third most common cardiovascular disease [2]. For long lesions, Duo Extend smoothly overlaps with the Duo Hybrid to extend therapy.

Stents 105
article thumbnail

Elixir Medical PINNACLE I Study of LithiX IVL System Meets Primary Endpoints of Clinical Success

DAIC

Clinical success was defined as optimal stent expansion after final treatment with no in-hospital major adverse cardiovascular event (MACE). stent expansion at Maximum Calcium Site 96.7% interventional cardiologist at ZNA Cardiovascular Center in Antwerp, Belgium. . stent expansion at Maximum Calcium Site 96.7%

Stents 105
article thumbnail

Revolution Vibe CT System Now Available from GE Healthcare

DAIC

v As cardiovascular disease (CVD) continues to rise globally, vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. CCTA offers a non-invasive, cost-effective, and highly sensitive method for diagnosing coronary artery disease (CAD), making it a valuable tool for clinicians.

article thumbnail

Association of triglyceride-glucose index with the risk of incident aortic dissection and aneurysm: a large-scale prospective cohort study in UK Biobank

Cardiovascular Diabetology

Triglyceride-glucose (TyG) index is an emerging surrogate indicator of insulin resistance, which has been demonstrated as a risk factor for various cardiovascular diseases including coronary syndrome, in-stent.

Stents 64
article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

FDA Breakthrough Device Designation accelerates the review process for novel technologies that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, such as CAD, which impacts 7.8% Stent Related Adverse Events greater than 1 Year After PCI. of the U.S. population.

article thumbnail

Leveraging AI-Enabled Remote Cardiac Monitoring to Improve Cardiovascular Care

DAIC

Cardiovascular disease (CVD) remains the leading cause of death in the U.S. This article will explore how AI-driven diagnostics are reshaping cardiovascular medicine and how can healthcare leaders can leverage these innovations to improve patient care and control costs. That future isnt decades away. It is already here.

article thumbnail

GE HealthCare and Medis Medical Imaging Announce Collaboration Focused on Non-Invasive Coronary Assessments to Help Advance Precision Care in Treatment of Coronary Artery Disease

DAIC

Within the complex umbrella of cardiovascular disease, CAD is a type of heart disease that develops when the coronary arteries narrow and the heart cannot deliver enough oxygen-rich blood to the heart.